Leiden, The Netherlands, March 22, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced it has completed an influenza alliance with Taiwanese-based ADImmune Corporation. Under the terms of the deal, ADImmune will use Crucell's virosome technology to produce a virosomal adjuvanted influenza vaccine for specified markets: Taiwan, Japan and Macau. Additionally, ADImmune will produce influenza antigen, which Crucell may purchase for the production of its vaccine product, Inflexal® V. Crucell will obtain a 20% equity stake in ADImmune. Financial details were not disclosed.

"With the demand for Inflexal® V presently beating current market supply, Crucell is convinced of an excellent growth potential for its influenza vaccine," said Dr. Ronald H.P. Brus, Crucell's President and Chief Executive Officer. "Inflexal® V is a distinguishable product that we intend to expand further into existing and new markets. The future additional supply of antigen from ADImmune will increase our possibilities to do this."

ADImmune is already employing Crucell's PER.C6® technology to develop and commercialize a vaccine against Japanese encephalitis virus in Taiwan and China.

About Virosome Technology
Virosomal technology is a broadly applicable delivery system for antigens, DNA/RNA or therapeutic drugs. Virosomal based vaccines do not require additional adjuvants, which are known to cause adverse reactions such as irritation and inflammation at the injections site, to enhance the immune response. As a result, virosomal based vaccines have superior immunogenicity and tolerability. Inflexal® V is a virosomal adjuvanted influenza vaccine that has excellent safety and tolerability. Epaxal® is the first virosomal adjuvanted vaccine for Hepatitis A, with excellent efficacy, providing immunity for up to 20 years.